Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

Pediatric Infectious Disease Journal

Volumn 28, Issue 2, 2009, Pages 159-161

  King, Jennifer R ^a   Acosta, Edward P ^a   Yogev, Ram ^b   Wiznia, Andrew ^c   Kraimer, Joyce ^d   Graham, Bobbie ^e   Carey, Vincent ^f   Britto, Paula ^f   Jean Philippe, Patrick ^g   Moye, John ^h   Watson, Douglas ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JACOBI MEDICAL CENTER   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ; LOPINAVIR; PYRIMIDINONE DERIVATIVE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE; VIRUS RESISTANCE; DRUG COMBINATION; DRUG INTERACTION; FEMALE; MALE; PRESCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRIMIDINONES; RITONAVIR;

EID: 61949484973     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181861d8b     Document Type: Article

References (11)

1. Danner S, Burn S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients [abstract I 1925]. Presented at: 41st Inter- science Conference on Antimicrobial Agents and Chemotherapy; December 16 -19, 2001; Chicago, IL.
2. Dailly E, Allavena C, Raffi F, et al. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. Br J Clin Pharm.2004;60: 32-34.
3. Bartelink IH, Rademaker CMA, Schobben A, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet.2006;45:1077-1097.
4. Turner ML, Reed-Walker K, King JR, et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. JChromatogr B Analyt Technol Biomed Life Sci.2003;784:331-341.
5. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J.2003;22:216-224.
6. Starr SE, Fletcher CV, Spector SA, et al. For the Pediatric AIDS Clinical Trials Group 382 Team. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med.1999;341:1874-1881.
7. Hsu A, Isaacson J, Burn S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother.2003: 47:350-359.
8. Bergshoeff AS, Fraaij PL, Ndagijimana J, et al. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1 infected children. J Acquir Immune Defic Syndr.2005;39:63-68.
9. Sustiva (efavirenz) capsules and tablets [US prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2007.
10. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr.2007;45:133-136.
11. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur JMed Res.2006;11:377-380.